Geert Maertens
Chairman SAB
Biochemistry
Bay Zoltan Nonprofit Public Ltd. for Applied Research
Belgium
Biography
Dr. Geert Maertens, PhD served as Chief Scientific Officer and Vice President of Corporate Development at Biocartis S.A. Dr. Maertens serves as Vice President of Corporate Development at GENimmune NV. Dr. Maertens joined Innogenetics in 1990, where he initiated the hepatitis C research program. In 1993, Dr. Maertens became responsible for an extended program including hepatitis B and C diagnostic and therapeutic developments, and was appointed as Senior Scientist in 1996. He is the main inventor on more than 20 HCV and HBV patent families. After heading Innogenetics' Infectious Diseases Business Unit in 2000, he became responsible for the hepatitis C vaccine development program. He was responsible for the hepatitis C vaccine developments in 2002. During recent years, he headed the therapeutic HBV, HCV, and HPV vaccine and mAb activities as program and portfolio manager. He later headed the development of therapeutic vaccines as Program and Portfolio Manager. He has authored more than 80 peer-reviewed publications. Dr. Maertens obtained his PhD in Molecular Biology in 1989 and Master's degree in Biology from the University of Gent in 1984.
Research Interest
Geert Maertens has research interest in Molecular Diagnostics
